Author

K. A. Janeway

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Approach:genetic perturbation / CRISPR· 1 Approach:statistical model· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

A. J. Church· 1 shared A. L. Hong· 1 shared A. Sayeed· 1 shared A. Tracy· 1 shared A. Ward· 1 shared B. D. Crompton· 1 shared B. D. Kynnap· 1 shared B. McSteen· 1 shared

Activity by Year

2018-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. J. Church

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

PARP inhibition in Ewing sarcoma: impact of germline DNA damage repair defects and activation of immunoregulatory pathways

L. M. Maurer, R. E. Venier, E. Mukherjee, C. M. Julian, J. D. Daley, N. G. Bailey, M. F. Jacobs, C. Kumar-Sinha, H. Raphel, K. Weiss, K. A. Janeway, R. Mody, P. C. Lucas, L. M. McAllister-Lucas, K. M. Bailey

This study shows that Ewing sarcoma cells with germline BARD1 mutations are sensitive to PARP inhibitors and that PARP inhibition increases PD-L1 expression, suggesting potential for combination immunotherapy.

bioRxiv · Sep 18, 2020 · PreprintCancer Biology

Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition

A. L. Hong, Y.-Y. Tseng, J. A. Wala, W. J. Kim, B. D. Kynnap, M. B. Doshi, G. Kugener, G. J. Sandoval, T. P. Howard, J. Li, X. Yang, M. Tillgren, M. Ghandi, A. Sayeed, R. Deasy, , W. Hahn

This study identifies SMARCB1 loss as critical for RMC survival and shows proteasome inhibition as a potential therapeutic strategy.

bioRxiv · Dec 5, 2018Cancer Biology